Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma

Blood (2012) 119 (24): 5772–5781.

https://doi.org/10.1182/blood-2011-07-366633

Published: 2012

Includes: Supplemental data

Journal Articles

Blockade of XBP1 Splicing by Inhibition of IRE1α Is a Promising Therapeutic Option in Multiple Myeloma

Blood (2011) 118 (21): 133.

https://doi.org/10.1182/blood.V118.21.133.133

Published: 2011

Journal Articles

PI3K/p110δ is a novel therapeutic target in multiple myeloma

Blood (2010) 116 (9): 1460–1468.

https://doi.org/10.1182/blood-2009-06-222943

Published: 2010

Includes: Supplemental data

Journal Articles

Biologic sequelae of IκB kinase (IKK) inhibition in multiple myeloma: therapeutic implications

Teru Hideshima, Dharminder Chauhan, Tanyel Kiziltepe, Hiroshi Ikeda, Yutaka Okawa, Klaus Podar, Noopur Raje, Alexei Protopopov, Nikhil C. Munshi, Paul G. Richardson, Ruben D. Carrasco, Kenneth C. Anderson

Blood (2009) 113 (21): 5228–5236.

https://doi.org/10.1182/blood-2008-06-161505

Published: 2009

Journal Articles

SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK

Yutaka Okawa, Teru Hideshima, Paul Steed, Sonia Vallet, Steven Hall, Ken Huang, John Rice, Amy Barabasz, Brianna Foley, Hiroshi Ikeda, Noopur Raje, Tanyel Kiziltepe, Hiroshi Yasui, Sotaro Enatsu, Kenneth C. Anderson

Blood (2009) 113 (4): 846–855.

https://doi.org/10.1182/blood-2008-04-151928

Published: 2009

Includes: Supplemental data

Journal Articles

The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia

Blood (2007) 110 (13): 4417–4426.

https://doi.org/10.1182/blood-2007-05-092098

Published: 2007

Journal Articles

In Vivo Effects of Zoledronic Acid on Bone Remodeling.

Samantha Pozzi, MD, Teru Hideshima, MD, Sonia Vallet, MD, Siddhartha Mukherjee, MD, Shweta Chhetri, Diana Cirstea, MD, Nileshwari Vaghela, Clare Thomas, Dilani Rosa, Hiroshi Ikeda, MD, Yutaka Okawa, MD, Tanyel Kiziltepe, PhD, Jesse Schoonmaker, Ernestina Schipani, MD, Mary Bouxsein, PhD, Kenneth C. Anderson, MD, Noopur Raje, MD

Blood (2007) 110 (11): 3520.

https://doi.org/10.1182/blood.V110.11.3520.3520

Published: 2007

Journal Articles

Targeting CCR1 for the Treatment of Osteolytic Bone Disease in Multiple Myeloma.

Sonia Vallet, MD, Noopur Raje, MD, MariaTeresa Fulciniti, Kenji Ishitsuka, MD, Teru Hideshima, MD, Klaus Podar, MD, Samantha Pozzi, MD, Iris Breitkreutz, MD, Tanyel Kiziltepe, PhD, Yutaka Okawa, MD, Hiroshi Ikeda, MD, Loredana Santo, MD, Siddhartha Mukherjee, MD, Nileshwari Vaghela, Diana Cirstea, MD, Mario Boccadoro, MD, Kenneth C. Anderson, MD

Blood (2007) 110 (11): 2503.

https://doi.org/10.1182/blood.V110.11.2503.2503

Published: 2007

Journal Articles

Preclinical Validation of a Clinical Grade Novel Specific Small Molecule Cyclin D1 Inhibitor, P276-00 for the Treatment of Multiple Myeloma.

Blood (2007) 110 (11): 256.

https://doi.org/10.1182/blood.V110.11.256.256

Published: 2007

Journal Articles

Inhibition of Hsp90 Targets Multiple Myeloma Cell Growth, Angiogenesis, and Osteoclastogenesis in the BM Microenvironment.

Yutaka Okawa, Teru Hideshima, Hiroshi Ikeda, Sonia Vallet, Tanyel Kiziltepe, Noopur Raje, Hiroshi Yasui, Sotaro Enatsu, Samantha Pozzi, Iris Breitkreutz, Klaus Podar, Paul G. Richardson, Kenneth C. Anderson

Blood (2007) 110 (11): 2522.

https://doi.org/10.1182/blood.V110.11.2522.2522

Published: 2007

Journal Articles

Multiple Myeloma Cell-Osteoblast Interaction Results in Impaired Bone Formation.

Sonia Vallet, MD, Teru Hideshima, MD, Samantha Pozzi, MD, Nileshwari Vaghela, Gaurav Gharti-Chhetri, Siddhartha Mukherjee, MD, Iris Breitkreutz, MD, Tanyel Kiziltepe, PhD, Yutaka Okawa, MD, Hiroshi Ikeda, MD, Loredana Santo, MD, Diana Cirstea, MD, Mario Boccadoro, MD, Kenneth C. Anderson, MD, Noopur Raje, MD

Blood (2007) 110 (11): 4764.

https://doi.org/10.1182/blood.V110.11.4764.4764

Published: 2007

Journal Articles

Delineation of Canonical and Non-Canonical NF-κB Pathways in Multiple Myeloma: Therapeutic Implications.

Teru Hideshima, MD, PhD, Noopur Raje, MD, Ruben Carrasco, MD, PhD, Hiroshi Ikeda, MD, PhD, Yutaka Okawa, MD, PhD, Tanyel Kiziltepe, PhD, Sonia Valet, MD, Samantha Pozzi, MD, Dharminder Chauhan, PhD, Constantine Mitsiades, MD, PhD, Klaus Podar, MD, PhD, Yu-Tzu Tai, PhD, Nikhil C. Munshi, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD

Blood (2007) 110 (11): 670.

https://doi.org/10.1182/blood.V110.11.670.670

Published: 2007

Journal Articles

MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts

Blood (2007) 110 (10): 3744–3752.

https://doi.org/10.1182/blood-2007-05-093294

Published: 2007

Includes: Supplemental data

Journal Articles

JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells

Tanyel Kiziltepe, Teru Hideshima, Kenji Ishitsuka, Enrique M. Ocio, Noopur Raje, Laurence Catley, Chun-Qi Li, Laura J. Trudel, Hiroshi Yasui, Sonia Vallet, Jeffery L. Kutok, Dharminder Chauhan, Constantine S. Mitsiades, Joseph E. Saavedra, Gerald N. Wogan, Larry K. Keefer, Paul J. Shami, Kenneth C. Anderson

Blood (2007) 110 (2): 709–718.

https://doi.org/10.1182/blood-2006-10-052845

Published: 2007

Includes: Supplemental data

Journal Articles

JS-K, a GST-Activated Nitric Oxide Generator, Induces DNA-Double Strand Breaks and Inhibits Growth and Survival of Multiple Myeloma Cells In Vitro and In Vivo .

Tanyel Kiziltepe, PhD, Teru Hideshima, Noopur Raje, Kenji Ishitsuka, Enrique M. Ocio, Laurence Catley, Chun-Qi Li, Laura Trudel, Hiroshi Yasui, Norihiko Shirashi, Yu-Tzu Tai, Dharminder Chauhan, Constantine Mitsiades, Joseph E. Saavedra, Gerald N. Wogan, Larry K. Keefer, Paul J. Shami, Kenneth C. Anderson

Blood (2006) 108 (11): 3453.

https://doi.org/10.1182/blood.V108.11.3453.3453

Published: 2006

Journal Articles

Targeting Cyclin D1 in the Treatment of Multiple Myeloma: Preclinical Validation of a Novel Specific Small Molecule Cyclin D1 Inhibitor, P276-00.

Noopur Raje, MD, Teru Hideshima, MD,PhD, Sonia Vallet, MD, Shweta Chhetri, Constantine Mitsiades, MD,PhD, Melissa Rooney, Hiroshi Yasui, Tanyel Kiziltepe, Klaus Podar, Yutaka Okawa, Hiroshi Ikeda, Dharminder Chauhan, Nikhil C. Munshi, Somesh Sharma, Himanshu Parikh, Bruce Chabner, Kenneth C. Anderson

Blood (2006) 108 (11): 3454.

https://doi.org/10.1182/blood.V108.11.3454.3454

Published: 2006

Journal Articles

BIRB796 Inhibits p38 MAPK/Hsp27 Pathway and Enhances Cytotoxicity Triggered by Bortezomib, Hsp90 Inhibitor, and Dexamethasone in Multiple Myeloma.

Hiroshi Yasui, MD, PhD, Teru Hideshima, M.D., Ph.D., Hiroshi Ikeda, M.D., Ph.D., Janice Jin, M.D., Enrique M. Ocio, D., Ph.D., Tanyel Kiziltepe, Ph.D, Yutaka Okawa, M.D., Ph.D., Sonia Vallet, M.D., Ph.D., Shweta Chhetri, Kenji Ishitsuka, M.D., Ph.D., Yu-Tzu Tai, Ph.D., Klaus Podar, M.D., Ph.D., Dharminder Chauhan, Ph.D., Chris Pargellis, Ph.D., Neil Moss, Ph.D., Noopur Raje, M.D., Ph.D., Kenneth C. Anderson, M.D.

Blood (2006) 108 (11): 3440.

https://doi.org/10.1182/blood.V108.11.3440.3440

Published: 2006

Journal Articles

Epigenetic Modulation by Vidaza™ induces Apoptosis and Overcomes In Vitro Drug Resistance in Human Multiple Myeloma Cells.

Tanyel Kiziltepe, PhD, Laurence Catley, MD, Teru Hideshima, MD,PhD, Noopur Raje, MD, Hiroshi Yasui, MD,PhD, Sonia Vallet, MD, Hiroshi Ikeda, MD,PhD, Yutaka Okawa, MD,PhD, Kenneth C. Anderson, MD

Blood (2006) 108 (11): 5001.

https://doi.org/10.1182/blood.V108.11.5001.5001

Published: 2006

Journal Articles

p38MAPK Inhibitor LSN2322600 Modulates the Bone Marrow Microenvironment and Inhibits Osteoclastogenesis in Multiple Myeloma.

Kenji Ishitsuka, MD, PhD, Teru Hideshima, M.D., Ph.D., Paola Neri, M.D., Ph.D., Sonia Vallet, M.D., Ph.D., Norihiko Shiraishi, Ph.D., Noopur Raje, M.D., Zhenxin Shen, M.D., Ph.D., Tanyel Kiziltepe, Ph.D., Enrique M. Ocio, M.D., Ph.D., Klaus Podar, M.D., Ph.D., Dharminder Chauhan, Ph.D., Nikhil Munshi, M.D., Robert M. Campbell, Ph.D., Alfonso De Dios, Ph.D., Chuan Shih, Ph.D., James J. Starling, Ph.D., Kazuo Tamura, M.D., Ph.D., Kenneth C. Anderson, M.D.

Blood (2006) 108 (11): 5042.

https://doi.org/10.1182/blood.V108.11.5042.5042

Published: 2006

Journal Articles

Novel Etodolac Analog SDX-308 (CEP-18082) Induces Cytotoxicity in Multiple Myeloma Cells Associated with Inhibition of Wnt/β-Catenin Pathway.

Hiroshi Yasui, MD, PhD, Teru Hideshima, M.D., Ph.D., Hiroshi Ikeda, M.D., Ph.D., Enrique M. Ocio, M.D., Ph.D., Tanyel Kiziltepe, Ph.D., Sonia Vallet, M.D., Ph.D., Yutaka Okawa, M.D., Ph.D., Shweta Chhetri, Kumar Sukhdeo, Kenji Ishitsuka, M.D., Ph.D., Klaus Podar, M.D., Ph.D., Noopur Raje, M.D., Ph.D., Dharminder Chauhan, Ph.D., Daniel R. Cattasco, M.D., Ph.D., Kenneth C. Anderson, M.D.

Blood (2006) 108 (11): 5005.

https://doi.org/10.1182/blood.V108.11.5005.5005

Published: 2006

NARROW

Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma

Blockade of XBP1 Splicing by Inhibition of IRE1α Is a Promising Therapeutic Option in Multiple Myeloma

PI3K/p110δ is a novel therapeutic target in multiple myeloma

Biologic sequelae of IκB kinase (IKK) inhibition in multiple myeloma: therapeutic implications

SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK

The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia

In Vivo Effects of Zoledronic Acid on Bone Remodeling.

Targeting CCR1 for the Treatment of Osteolytic Bone Disease in Multiple Myeloma.

Preclinical Validation of a Clinical Grade Novel Specific Small Molecule Cyclin D1 Inhibitor, P276-00 for the Treatment of Multiple Myeloma.

Inhibition of Hsp90 Targets Multiple Myeloma Cell Growth, Angiogenesis, and Osteoclastogenesis in the BM Microenvironment.

Multiple Myeloma Cell-Osteoblast Interaction Results in Impaired Bone Formation.

Delineation of Canonical and Non-Canonical NF-κB Pathways in Multiple Myeloma: Therapeutic Implications.

MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts

JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells

JS-K, a GST-Activated Nitric Oxide Generator, Induces DNA-Double Strand Breaks and Inhibits Growth and Survival of Multiple Myeloma Cells In Vitro and In Vivo .

Targeting Cyclin D1 in the Treatment of Multiple Myeloma: Preclinical Validation of a Novel Specific Small Molecule Cyclin D1 Inhibitor, P276-00.

BIRB796 Inhibits p38 MAPK/Hsp27 Pathway and Enhances Cytotoxicity Triggered by Bortezomib, Hsp90 Inhibitor, and Dexamethasone in Multiple Myeloma.

Epigenetic Modulation by Vidaza™ induces Apoptosis and Overcomes In Vitro Drug Resistance in Human Multiple Myeloma Cells.

p38MAPK Inhibitor LSN2322600 Modulates the Bone Marrow Microenvironment and Inhibits Osteoclastogenesis in Multiple Myeloma.

Novel Etodolac Analog SDX-308 (CEP-18082) Induces Cytotoxicity in Multiple Myeloma Cells Associated with Inhibition of Wnt/β-Catenin Pathway.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only